



Oregon Prescription Drug
Affordability Board

Oregon Prescription Drug Affordability Board Regular Meeting
Wednesday, July 15, 2026
Minutes approved by the board on August 19, 2026

Web link to the meeting video: <https://youtu.be/kSp5erHOLtk>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20260715-PDAB-document-package.pdf>

Call to order: Vice Chair Dan Hartung called the meeting to order at 8:02 a.m.

Roll call:

Present: Vice Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, John Murray, Noelle Redmond

Absent: Chair Shelley Bailey

New board member: Vice Chair Hartung introduced and welcomed new board member Noelle Redmond, who is the director of clinical pharmacy services at Cambia Health Solutions/Regence Blue Cross Blue Shield in Portland. View at video minute [00:01:00](#).

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: John Murray, Chris Laman, and Dan Hartung provided statements. View at video minute [00:01:57](#).

Approval of board minutes: Vice Chair Hartung approved by consensus the corrected minutes of June 17, 2026, as shown on [Pages 2-3](#) of the agenda materials. Staff corrected a misspelled name in the board declaration section of the minutes and added a note about the correction. View at video minute [00:04:09](#).

PDAB program update: Sarah Young, PDAB executive director, provided a program update. View at video minute [00:05:15](#).

General and drug review public comment periods: Charlie Fisher of OSPIRG and MaryAnne Cooper of Regence BlueCross Blue Shield of Oregon, provided general public comments for the board. View at video minute [00:11:26](#). The board received [one written general comment](#). During the drug review comment period, Lorren Sandt of Caring Ambassadors Program, and Terri Lee of Merck, spoke about Keytruda. View at video minute [00:19:39](#). The board received [seven drug review written comments](#).

Oregon insurance regulation presentation: Numi Lee Griffith, senior policy advisor with the Division of Financial Regulation, provided a presentation about Oregon insurance regulation. View the slides on [Pages 4-22](#). View the presentation at video minute [00:28:05](#).



Drug review: Keytruda, Verzenio, and Xeljanz: Cortnee Whitlock, PDAB program and senior policy analyst, presented the drug review reports, followed by board discussion. They began by reviewing and discussing the [2026 drug review roadmap](#) and [scoring rubric options](#). View the roadmap and scoring rubric discussion at video minute [01:13:11](#). View the [Keytruda](#) discussion at video minute [01:37:09](#). View the [Verzenio](#) discussion at video minute [02:03:44](#). View the [Xeljanz](#) discussion at video minute [02:13:05](#).

Board discussion: policy concepts for annual report: Cortnee Whitlock presented slides with policy concepts for consideration to prioritize and research, followed by board discussion. The board identified four concepts to research for further discussion. View the slides on [Pages 31-41](#). View at video minute [02:39:18](#).

Announcements: Vice Chair Hartung announced the next board meeting will be August 19, 2026, at 8 a.m. View at video minute [03:36:20](#).

Adjournment: Vice Chair Hartung adjourned the meeting at 11:43 a.m. with all board members in agreement. View at video minute [03:36:37](#).